Evidence map›Paper›PMID 38516587›Full record

ReviewRSC medicinal chemistry2024

Indole-containing pharmaceuticals: targets, pharmacological activities, and SAR studies.

Wei Zeng, Chi Han, Sarah Mohammed, Shanshan Li, Yixuan Song, Fengxia Sun, Yunfei Du

Abstract readReview
In one paragraph

Review in RSC medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Synthetic strategies and therapeutic insights into FDA-approved indole-containing drugs.Journal of enzyme inhibition and medicinal chemistry · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Discovery of a Potent Small Molecule Antagonist of GRPR for the Treatment of Pruritus.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei ZengSchool of Pharmaceutical Science and Technology, Tianjin University Tianjin 300072 China duyunfeier@tju.edu.cn.
Chi HanSchool of Pharmaceutical Science and Technology, Tianjin University Tianjin 300072 China duyunfeier@tju.edu.cn.
Sarah MohammedSchool of Pharmaceutical Science and Technology, Tianjin University Tianjin 300072 China duyunfeier@tju.edu.cn.
Shanshan LiSchool of Pharmaceutical Science and Technology, Tianjin University Tianjin 300072 China duyunfeier@tju.edu.cn.
Yixuan SongDepartment of Chemical Engineering & Biotechnology, University of Cambridge CB2 3RA Cambridge UK.
Fengxia SunResearch Center for Chemical Safety & Security and Verification Technology & College of Chemical and Pharmaceutical Engineering, Hebei University of Science and Technology Shijiazhuang 050018 China fxsun001@163.com.
Yunfei DuSchool of Pharmaceutical Science and Technology, Tianjin University Tianjin 300072 China duyunfeier@tju.edu.cn.ORCID https://orcid.org/0000-0002-0213-2854

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Indole is a prestigious heterocyclic skeleton widely found in both naturally-occurring and biologically-active compounds. Pharmaceutical agents containing an indole skeleton in their framework possess a wide range of pharmacological properties, including antiviral, antitumor, analgesic, and other therapeutic activities, and many indole-containing drugs have been proven to have excellent pharmacokinetic and pharmacological effects. Over the past few decades, the FDA has approved over 40 indole-containing drugs for the treatment of various clinical conditions, and the development of indole-related drugs has attracted significant attention from medicinal chemists. This review aims to provide an overview of all the approved drugs that contain an indole nucleus, focusing on their targets, pharmacological activities, and SAR studies.

Identifiers

PMID38516587
PMCPMC10953485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.